Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-Positive breast cancer patients treated with chemotherapy and HER2-Targeted agents in the CherLOB trial

Annals of Oncology

Volumn 27, Issue 10, 2016, Pages 1867-1873

  Dieci, M V ^a,b   Prat, A ^c,d,e   Tagliafico, E ^f   Pare L ^d   Ficarra, G ^g   Bisagni, G ^h   Piacentini, F ^f   Generali, D G ⁱ   Conte, P ^a,b   Guarneri, V ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^h S MARIA NUOVA HOSPITAL   (Italy)

ⁱ CREMONA HOSPITAL   (Italy)

Author keywords

Breast cancer; HER2; Immune signatures; Neoadjuvant; PAM50; Tumor infiltrating lymphocytes

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; PACLITAXEL; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; BIOPSY TECHNIQUE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION ASSAY; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN TISSUE; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; AGED; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CLINICAL TRIAL; FEMALE; GENETICS; IMMUNOLOGY; LARGE CORE NEEDLE BIOPSY; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BIOPSY, LARGE-CORE NEEDLE; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MICROARRAY ANALYSIS; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TRASTUZUMAB;

EID: 85014594946     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw262     Document Type: Article

References (28)

1. Perez EA, Romond EH, Suman VJ et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29: 3366-3373.
2. Vaz-Luis I, Ottesen RA, Hughes ME et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res 2012; 14: R129.
3. Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2- positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-640.
4. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2- positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32.
5. Guarneri V, Frassoldati A, Bottini A et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2- positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012; 30: 1989-1995.
6. Prat A, Bianchini G, Thomas M et al. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clin Cancer Res 2014; 20: 511-521.
7. Prat A, Carey LA, Adamo B et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst 2014; 106(8): 1-8.
8. Loi S, Michiels S, Salgado R et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014; 25: 1544-1550.
9. Dieci MV, Mathieu MC, Guarneri V et al. Prognostic and predictive value of tumorinfiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol 2015; 26: 1698-1704.
10. Loi S, Michiels S, Salgado R et al. Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Res 2013; 73(24 Suppl): S1-05.
11. Perez EA, Thompson EA, Ballman KV et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol 2015; 33: 701-708.
12. Salgado R, Denkert C, Demaria S et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an international TILs working group 2014. Ann Oncol 2015; 26: 259-271.
13. Guarneri V, Dieci MV, Frassoldati A et al. Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual Anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2- positive breast cancer. Oncologist 2015; 20: 1001-1010.
14. Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
15. Triulzi T, De Cecco L, Sandri M et al. Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. Oncotarget 2015; 6: 28173-28182.
16. Prat A, Pineda E, Adamo B et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 2015; 24(Suppl. 2): S26-S35.
17. Bindea G, Mlecnik B, Tosolini M et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39: 782-795.
18. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013; 39: 11-26.
19. Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 2007; 26: 373-400.
20. Ribas A, Robert C, Hodi FS et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J Clin Oncol 2015; 33: 3001.
21. Carey LA, Berry DA, Cirrincione CT et al. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J Clin Oncol 2015; 34: 542-549.
22. Pogue-Geile KL, Song N, Jeong JH et al. Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol 2015; 33: 1340-1347.
23. Loi S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology 2013; 2: e24720.
24. Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059.
25. Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol 2014; 15: e58-e68.
26. Denkert C, von Minckwitz G, Brase JC et al. Tumor Infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-Positive and TripleNegative primary breast cancers. J Clin Oncol 2015; 33: 983-991.
27. Salgado R, Denkert C, Campbell C et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol 2015; 1: 448-454.
28. Bianchini G, Pusztai L, Pienkowski T et al. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. Ann Oncol 2015; 26: 2429-2436.